MARIYA GILES: Open Payments
NPI 1902156862 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,813 in 90 payments from 20 companies in 2025. Trend: 2023 $671 · 2024 $1,236 · 2025 $1,813
Food & beverage: $1,761Consulting: $52
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $281 |
| CSL Behring | 15 | $248 |
| Novartis Pharmaceuticals Corporation | 18 | $218 |
| GENZYME CORPORATION | 7 | $142 |
| Genentech USA, Inc. | 4 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $105 |
| Pharming Healthcare, Inc. | 3 | $90 |
| GlaxoSmithKline, LLC. | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Blueprint Medicines Corporation | 2 | $73 |
Products named: DUPIXENT, AYVAKIT, TEZSPIRE, Xolair, Hizentra, AIRSUPRA, Andembry, RUCONEST.
Industry payments across WA — which companies pay providers there.
